Cargando…
IPM chemotherapy in cytokine refractory renal cell cancer
Renal cell carcinoma (RCC) is notoriously chemoresistant. Current management of metastatic disease usually includes immunological agents of which the most clearly evaluated is alpha interferon. Following the failure of such agents no clear second-line therapy exists. The use of a novel combination o...
Autores principales: | Shamash, J, Steele, J P, Wilson, P, Nystrom, M, Ansell, W, Oliver, R T D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377110/ https://www.ncbi.nlm.nih.gov/pubmed/12771915 http://dx.doi.org/10.1038/sj.bjc.6600934 |
Ejemplares similares
-
Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding
por: Shamash, J, et al.
Publicado: (2005) -
A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
por: Shamash, J, et al.
Publicado: (2008) -
Performance of the RHIC IPM
por: Connolly, R, et al.
Publicado: (2001) -
GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
por: Shamash, J, et al.
Publicado: (2007) -
GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours
por: Shamash, J, et al.
Publicado: (2007)